PTO/SB/05 (11-00)

· · ·		
Please type a plus sig	n (+) inside this box	 F

Approved for use through 10/31/2002. OMB 0651-0032 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control num

### UTILITY PATENT APPLICATION **TRANSMITTAL**

IOZ01-NP009 Attorney Docket No. Iozzo, Renato V. First Inventor Endorepellin: Methods and Compositions for Inhibiting Angiogenesis

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Express Mail Label No. EV044356728US

APPLICA	ATION ELEMENTS		ADDRESS TO: Assistant Commissioner for Patents Box Patent Application	
See MPEP chapter 600 con	ncerning utility patent application conte		Washington, DC 20231	
1. Submit an original and a Applicant claims	orm (e.g., PTO/SB/17) 7. CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix) mall entity status. 8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)			
See 37 CFR 1.27.  3. Specification [Total Pages 38 ] [Impelered arrangement set forth below]  - Descriptive title of the invention   Cross Reference to Related Applications   Statement Regarding Fed sponsored R & D   Reference to sequence listing, a table, or a computer program listing appendix   Background of the Invention   Brief Summary of the Invention   Brief Summary of the Drawings (if filed)   Detailed Description   Claim(s)   Abstract of the Disclosure   Total Pages   Jackground of Declaration   Total Pages   Jackground   Ja				
6. X Application Data Sheet. See 37 CFR 1.76 or its equivalent.  Other:				
18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:  Continuation Divisional Continuation-in-part (CIP) Of prior application No:  Frior application information: Examiner Group An Unit:  For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference.				
The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.  19. CORRESPONDENCE ADDRESS				
Customer Number or Bar C	24358 Sustainer No. or Atta	och bar code	or Correspondence address below	
Name				
Address			·	
City		Sta	ate Zip Code	
Country		Telepho	one Fax	
Name (Print/Type)	Janet B. Smith		Registration No. (Attorney/Agent) 45,461	
Signature	land of Anni	· /	Date 12/04/01	
2.3		<del></del>		

burden nour statement: This form's estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES ON COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

PTO/SB/17 (10-01)
Approved for use through 10/31/2002. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Passywork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## **ÉE TRANSMITTAL** for FY 2002

Patent fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT

704.00 (\$)

Complete if Known			
Application Number			
Filing Date	12/04/2001		
First Named Inventor	IOZZO, Renato V.		
Examiner Name			
Group Art Unit			
Attorney Docket No.	IOZ01-NP009	フ	

	METHOD OF PAYMENT		FEE CALCULATION (continued)					
	1. X The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to:		3. ADDITIONAL FEES					
	Deposit Account 50-0491		Large Small Entity Entity					
	Number	[50-0491	Fee Fee Fee Fee Description Fee Paid	_				
	Deposit Account	Thomas Jefferson University	105 130 205 65 Surcharge - late filing fee or oath	4				
		pe Any Additional Fee Required	127 50 227 25 Surcharge - late provisional filing fee or cover sheet	1				
		cant claims small entity status.	139 130 139 130 Non-English specification	4				
		37 CFR 1.27	147 2,520 147 2,520 For filing a request for ex parte reexamination	1				
	2.	rment Enclosed: ck C Credit card Money Dothe	112 920* 112 920* Requesting publication of SIR prior to Examiner action	┨				
	FEE CALCULATION		113 1,840* 113 1,840* Requesting publication of SIR after Examiner action	4				
9	1 BASIC	FILING FEE	115 110 215 55 Extension for reply within first month	4				
		ity Small Entity	116 400 216 200 Extension for reply within second month	┨				
n	Fee Fee Code (\$)		117 920 217 460 Extension for reply within third month	┨				
o	101 740	201 370 Utility filing fee 370.0	118 1,440 218 720 Extension for reply within fourth month	4				
ļ-i	106 330	206 165 Design filing fee	128 1,960 228 980 Extension for reply within fifth month	╛				
i i	107 510	207 255 Plant filing fee	119 320 219 160 Notice of Appeal	4				
8	108 740	208 370 Reissue filing fee	120 320 220 160 Filing a brief in support of an appeal	╛				
ļ	114 160	214 80 Provisional filing fee	121 280 221 140 Request for oral hearing	╛				
fu.		_	138 1,510 138 1,510 Petition to institute a public use proceeding	╛				
		SUBTOTAL (1) (\$) 370.00	140 110 240 55 Petition to revive - unavoidable	┨				
	2. EXTRA CLAIM FEES  Extra Claims Fee from below Fee Paid  Total Claims 15 -20** = X 9.00 = 0.00		141 1,280 241 640 Petition to revive - unintentional	4				
			Paid 142 1,280 242 640 Utility issue fee (or reissue)	4				
ř4				┨				
	Independent Claims	10 - 3** = 7 × 42.00 = 294.0	00 144 620 244 310 Plant issue fee	$\dashv$				
	Multiple Deper	ndent =	122 130 122 130 Petitions to the Commissioner	4				
			123 50 123 50 Processing fee under 37 CFR 1.17(q)	4				
	Large Entity Fee Fee	y Small Entity Fee Fee Fee Description	126 180 126 180 Submission of Information Disclosure Stmt	4				
	Code (\$) 103 18	Code (\$) 203 9 Claims in excess of 20	581 40 581 40 Recording each patent assignment per property (times number of properties)					
	102 84	202 42 Independent claims in excess of 3	146 740 246 370 Filing a submission after final rejection	١				
	104 280	204 140 Multiple dependent claim, if not paid	(37 CFR § 1.129(a))  149 740 249 370 For each additional invention to be	1				
	109 84	209 42 ** Reissue independent claims over original patent	examined (37 CFR § 1.129(b))	+				
	110 18	210 9 ** Reissue claims in excess of 20	179 740 279 370 Request for Continued Examination (RCE)	4				
		and over original patent	169 900 169 900 Request for expedited examination of a design application	1				
1	SUBTOTAL (2) (\$) 294.00		Other fee (specify)					
	**or number	r previously paid, if greater; For Reissues, see above	Reduced by Basic Filing Fee Paid SUBTOTAL (3) (\$) 40.00					

SUBMITTED BY	SUBMITTED BY Complete (if applicable)			f applicable)
Name (Print/Type)	Janet B. Smith	Registration No. (Attorney/Agent) 45,461	Telephone	(215) 503-2386
Signature	Jane Robon Wh		Date	12/04/2001

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ATTORNEY DOCKET NO.:

IOZ01-NP009

TITLE:

Endorepellin: Methods and Compositions for Inhibiting

Angiogenesis

INVENTOR(S):

Iozzo, Renato V.

"Express Mail" Label No. EV0443567283US Date of Deposit – December 4, 2001

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231.

Typed Name: Janet B. Smith

Box Patent Application
Commissioner of Patents & Trademarks

Washington, DC 20231

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In <u>re</u> Application : Group Art Unit: Unknown

Iozzo, Renato V., et al. : Examiner: Unknown

.

Serial No.: Unknown : Attorney Docket

IOZ01-NP009

Filed: December 4, 2001 :

For: Endorepellin: Methods and Compositions for Inhibiting Angiogenesis

**Assistant Commissioner for Patents** 

Washington, D.C. 20231

Sir:

# STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE WITH 37 CFR §§ 1.821 THROUGH 1.825.

- (X) I hereby state, in accordance with the requirements of 37 C.F.R. §1.821(f), that the contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. §1.821(c) and (e), respectively are the same.
- (X) I hereby state that the submission filed in accordance with 37 C.F.R. §1.821(g) does not include new matter.
- ( ) I hereby state that the submission filed in accordance with 37 C.F.R. §1.821(h) does not Include new matter or go beyond the disclosure in the international application as filed.
- () I hereby state that the amendments, made in accordance with 37 C.F.R. §1.825(a), included in the initial/substitute sheet(s) of the Sequence Listing are supported in the application, as filed, at pages \_\_\_\_\_. I hereby state that the substitute sheet(s) of the Sequence Listing does(do) not include new matter.
- ( ) I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 C.F.R. §1.825(b), is the same as the amended Sequence Listing.
- (X) I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 C.F.R. §1.825(d), contains identical data to that originally filed.

#### **DATA SHEET**

DOCKET NUMBER:

IOZ01-NP009

FILING TITLE:

Endorepellin: Methods and Compositions for Inhibiting

Angiogenesis

PRIORITY TO BE CLAIMED:

APPLICANT:

THOMAS JEFFERSON UNIVERSITY

1020 Walnut Street Philadelphia, PA 19107 United States of America

**INVENTORS:** 

Iozzo, Renato V.

1334 Beumont Drive Gladwyne, PA 19035

US

Respectfully submitted,

Janet B. Smith

Registration No. 45,461

Agent for Applicant

THOMAS JEFFERSON UNIVERSITY

1020 Walnut Street – Suite 630 Philadelphia, PA 19107-5587

Telephone: (215-503-2386) Facsimile: (215-923-3613)

Date: December 4, 2001